RCKT Q3 2024 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$69M

Net Income

-$67M

EPS (Diluted)

$-0.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$54M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$394M

Total Liabilities

$64M

Stockholders' Equity

$330M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$69M	-$65M	-6.1%
Net Income	-$67M	-$62M	-7.8%